Lixte Biotechnology Holdings, INC. (LIXT) — 8-K Filings

All 8-K filings from Lixte Biotechnology Holdings, INC.. Browse 44 Current Event Report reports with AI-powered summaries and risk analysis.

8-K Filings (44)

Lixte Biotechnology Files 8-K on Agreements & Equity — Dec 31, 2025 Risk: medium
Lixte Biotechnology Holdings, Inc. filed an 8-K on December 31, 2025, reporting on a material definitive agreement, unregistered sales of equity securities, and
Lixte Biotechnology Enters Material Definitive Agreement — Dec 23, 2025 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on December 17, 2025, that it entered into a material definitive agreement. The company, incorporated in Delaware w
Lixte Biotech Enters and Terminates Agreements — Dec 22, 2025 Risk: medium
Lixte Biotechnology Holdings, Inc. reported on December 16, 2025, the entry into and termination of material definitive agreements. The company, incorporated in
Lixte Biotechnology Files 8-K on Shareholder Vote Matters — Dec 11, 2025 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on December 11, 2025, reporting on events that occurred on December 8, 2025. The filing indicates a submission o
8-K Filing — Nov 25, 2025
Lixte Biotechnology Files 8-K — Sep 11, 2025 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on September 11, 2025, reporting an event that occurred on September 10, 2025. The filing is a current report pu
Lixte Biotech Appoints New Chief Medical Officer — Sep 4, 2025 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on September 3, 2025, the appointment of Dr. John B. "Jack" Greene as Chief Medical Officer. Dr. Greene, previously
Lixte Biotechnology Files 8-K — Aug 19, 2025 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on August 18, 2025, reporting other events and financial statements. The company, incorporated in Delaware, has
Lixte Biotechnology Holdings Files 8-K — Aug 14, 2025 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on August 14, 2025, reporting events as of August 13, 2025. The filing indicates the company's principal executi
Lixte Biotech Appoints New Chief Medical Officer — Jul 21, 2025 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on July 21, 2025, that its Board of Directors appointed Dr. John B. McCarthy as Chief Medical Officer, effective Ju
Lixte Biotechnology Files 8-K on Stock and Warrants — Jul 16, 2025 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on July 16, 2025, reporting an event that occurred on July 15, 2025. The filing indicates changes related to its
Lixte Biotechnology Raises $1.5M in Preferred Stock Sale — Jul 11, 2025 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on July 11, 2025, that it entered into a securities purchase agreement on July 9, 2025. This agreement involves the
Lixte Biotechnology Files 8-K for Material Agreement — Jul 8, 2025 Risk: medium
On July 8, 2025, Lixte Biotechnology Holdings, Inc. filed an 8-K report detailing a material definitive agreement entered into on July 3, 2025. The filing also
Lixte Biotechnology Announces Material Definitive Agreement — Jul 3, 2025 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on July 2, 2025, that it entered into a material definitive agreement. The company also reported on unregistered sa
Lixte Biotech Announces Material Agreement, Officer Changes — Jun 17, 2025 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on June 16, 2025, the entry into a material definitive agreement. The company also reported the departure of direct
Lixte Biotechnology Changes Principal Executive Offices — May 20, 2025 Risk: low
On May 16, 2025, LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed an 8-K report detailing an event. The filing indicates a change in the company's principal executive o
Lixte Biotechnology Faces Delisting Notice — Apr 18, 2025 Risk: high
Lixte Biotechnology Holdings, Inc. filed an 8-K on April 17, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule. The company i
Lixte Biotechnology Files 8-K — Mar 31, 2025 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on March 31, 2025, reporting on other events and financial statements. The company, incorporated in Delaware wit
Lixte Biotechnology Holdings Files 8-K — Mar 27, 2025 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on March 27, 2025, reporting other events and financial statements. The company, incorporated in Delaware with i
Lixte Biotechnology Enters Material Definitive Agreement — Mar 14, 2025 Risk: medium
Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement on March 11, 2025. The company, incorporated in Delaware with its principal exec
Lixte Biotechnology Holdings, Inc. Files 8-K — Mar 11, 2025 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on March 11, 2025, reporting on events that occurred on March 10, 2025. The filing indicates the company's princ
LIXTE BIOTECHNOLOGY FILES 8-K REPORT — Feb 25, 2025 Risk: low
On February 25, 2025, LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed an 8-K report. The filing primarily concerns "Other Events" and "Financial Statements and Exhibit
Lixte Biotechnology Faces Delisting Concerns — Feb 21, 2025 Risk: high
Lixte Biotechnology Holdings, Inc. filed an 8-K on February 21, 2025, reporting a notice of delisting or failure to meet continued listing standards as of Febru
Lixte Biotechnology Files 8-K on Definitive Agreement & Equity Sales — Feb 13, 2025 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on February 11, 2025, the entry into a material definitive agreement and unregistered sales of equity securities. T
Lixte Biotechnology Files 8-K on Material Agreement — Jan 6, 2025 Risk: medium
On January 6, 2025, Lixte Biotechnology Holdings, Inc. filed an 8-K report detailing a material definitive agreement. The filing indicates the company's princip
Lixte Biotechnology Changes HQ, Reports Officer/Director Updates — Dec 27, 2024 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on December 23, 2024, a change in its principal executive offices to 680 East Colorado Boulevard, Suite 180, Pasade
Lixte Biotechnology Holdings Files 8-K on Shareholder Vote Matters — Dec 20, 2024 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on December 20, 2024, reporting on a submission of matters to a vote of security holders that occurred on Decemb
Lixte Biotechnology Enters Material Definitive Agreement — Dec 2, 2024 Risk: medium
Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement on November 29, 2024. The filing does not specify the nature of the agreement or
Lixte Biotechnology Faces Delisting Concerns — Oct 23, 2024 Risk: high
Lixte Biotechnology Holdings, Inc. filed an 8-K on October 23, 2024, reporting a notice of delisting or failure to meet continued listing standards as of Octobe
Lixte Biotechnology Files 8-K — Sep 5, 2024 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on September 4, 2024, reporting an event related to its financial statements and exhibits. The filing does not c
Lixte Biotechnology Files 8-K — Aug 26, 2024 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on August 26, 2024, reporting other events and financial statements. The company, incorporated in Delaware, is l
Lixte Biotechnology Faces Delisting Notice — Aug 23, 2024 Risk: high
Lixte Biotechnology Holdings, Inc. filed an 8-K on August 23, 2024, reporting a notice of delisting or failure to satisfy a continued listing rule or standard,
Lixte Biotech Raises $1.9M via Stock and Warrant Sale — Aug 19, 2024 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on August 15, 2024, that it has entered into a securities purchase agreement with an institutional investor. The ag
Lixte Biotechnology Enters Material Definitive Agreement — Jul 12, 2024 Risk: medium
Lixte Biotechnology Holdings, Inc. entered into a material definitive agreement on July 8, 2024. The filing does not specify the nature of the agreement or any
Lixte Biotech Appoints New CMO, Adds Director — Jul 11, 2024 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on July 9, 2024, the appointment of Dr. John B. McCarthy as Chief Medical Officer and the election of Dr. Alan L. R
Lixte Biotechnology Enters Material Agreement — Jun 14, 2024 Risk: medium
Lixte Biotechnology Holdings, Inc. entered into a Material Definitive Agreement on June 10, 2024. The filing also includes financial statements and exhibits rel
Lixte Biotech Appoints New CMO, Director — Jun 5, 2024 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on May 31, 2024, the appointment of Dr. John B. McCarthy as Chief Medical Officer and the election of Ms. Susan A.
Lixte Biotech Appoints New CMO, Adds Director — May 29, 2024 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on May 24, 2024, the appointment of Dr. John B. McCarthy as Chief Medical Officer and the election of Dr. Alistair
Lixte Biotechnology Files 8-K — May 20, 2024 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on May 20, 2024, reporting other events and financial statements. The company, incorporated in Delaware, has its
Lixte Biotechnology Holdings Files 8-K — Mar 28, 2024 Risk: low
Lixte Biotechnology Holdings, Inc. filed an 8-K on March 28, 2024, reporting an event on March 27, 2024. The filing indicates changes related to common stock an
Lixte Biotechnology Secures $1.5M Funding — Mar 22, 2024 Risk: medium
Lixte Biotechnology Holdings, Inc. announced on March 21, 2024, that it has entered into a securities purchase agreement with an investor. The agreement allows
LIXTE Files 8-K on Common Stock & Warrants Activity — Feb 27, 2024 Risk: medium
LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed an 8-K on February 27, 2024, reporting under "Other Events" and "Financial Statements and Exhibits." The filing indicat
LIXTE Biotech Enters Material Definitive Agreement — Feb 26, 2024 Risk: medium
LIXTE BIOTECHNOLOGY HOLDINGS, INC. (LIXT) filed an 8-K on February 26, 2024, reporting an "Entry into a Material Definitive Agreement" and "Other Events" that o
LIXTE Biotech Updates Principal Executive Offices — Jan 30, 2024
LIXTE BIOTECHNOLOGY HOLDINGS, INC. filed an 8-K on January 30, 2024, reporting an event on January 29, 2024, to update its principal executive offices to 680 Ea

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX